First-of-its-Kind immune cell therapy trial launches for Tough-to-Treat blood cancer
NCT ID NCT04815356
Summary
This study is testing the safety and early effects of a new treatment called anti-CD22 CAR T-cell therapy for adults with hairy cell leukemia that has come back or not responded to other standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to better target the cancer, and then infuse them back. The main goal is to find a safe dose and see if this approach can reduce or eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.